Progression of Multiple Sclerosis: Understanding RRMS, SPMS, and PPMS

Last updated on:

March 2, 2026

Multiple sclerosis (MS) is not a single, uniform disease – it progresses differently in different people. Some individuals experience unpredictable flare-ups and recoveries for years, while others face a steady, unrelenting decline from the very beginning. Understanding the distinct progression patterns of MS is critical for clinical care, patient education, and disability support. Three primary disease courses shape how MS unfolds over a lifetime: Relapsing-Remitting MS (RRMS), Secondary-Progressive MS (SPMS), and Primary-Progressive MS (PPMS). Each has its own clinical characteristics, challenges, and implications for management.

Why disease course classification matters
Relapsing-remitting MS (RRMS)
What happens during a relapse?
What happens during remission?
Who is diagnosed with RRMS and when?
Managing RRMS
Secondary-progressive MS (SPMS)
The transition from RRMS to SPMS
What SPMS looks like clinically
Risk factors for earlier SPMS transition
Primary-progressive MS (PPMS)
How PPMS differs from the start
Age at onset and typical presentation
Why PPMS is particularly challenging
Comparing the three types: key differences at a glance

Why disease course classification matters

Before diving into each type, it helps to understand why classifying the course of MS matters at all. According to the U.S. Department of Veterans Affairs, categorizing MS into clinical subtypes provides a common language for clinicians, guides prognosis, and allows for more targeted research and treatment decisions. The four originally defined MS subtypes – RRMS, SPMS, PPMS, and the now less commonly used progressive-relapsing MS (PRMS) – were formally proposed in 1996 by the National Multiple Sclerosis Society’s Advisory Committee, driven by the need for standardized terminology in clinical trials and practice.

More recently, MS specialists have refined this classification further. Rather than treating these subtypes as fixed, separate categories, there is growing scientific consensus that RRMS and the progressive forms of MS exist on a continuum – one disease with shifting mechanisms over time. Two key descriptors now accompany each subtype: active or not active (whether relapses or new MRI lesions are occurring) and progressing or stable (whether disability is worsening independently of relapses). This updated approach enables more personalised treatment decisions.

Relapsing-remitting MS (RRMS)

RRMS is the most common form of multiple sclerosis. According to Brigham and Women’s Hospital, approximately 85% of all MS diagnoses are RRMS. This disease course is defined by clearly identifiable episodes – called relapses, flares, or attacks – in which new symptoms appear or existing ones worsen, followed by periods of partial or complete recovery known as remissions.

What happens during a relapse?

During a relapse, the immune system launches an inflammatory attack on the myelin sheath – the protective coating around nerve fibres in the brain and spinal cord. This disrupts nerve signalling and produces neurological symptoms. Cleveland Clinic describes typical relapse symptoms as including numbness or tingling, vision problems, fatigue, weakness, balance issues, and cognitive difficulties. A relapse usually develops over hours to a few days and can last for weeks. Individual relapses typically last a few weeks to two months.

Certain factors can trigger or worsen relapses. These include infections (even mild ones like urinary tract infections), heat exposure, smoking, and vitamin D deficiency. Importantly, what triggers a relapse in one person may have no effect on another.

What happens during remission?

Following a relapse, the body attempts to repair the damaged myelin – a process that can restore some or all lost function. However, repair is not always complete: the healing process produces scar tissue on the nervous system, which can cause lasting complications over time. During remission, symptoms may ease significantly or disappear altogether – but this does not mean the disease is inactive. Even between relapses, MS can cause subtle, ongoing damage known as Progression Independent of Relapse Activity (PIRA), which may slowly worsen disability without obvious symptom changes.

Who is diagnosed with RRMS and when?

The MS Society notes that RRMS is typically diagnosed in a person’s 30s or 40s, though it can appear in children and older adults. Women are two to three times more likely to be diagnosed with RRMS than men. The MS Trust explains that remission periods can vary widely – some people go years between relapses while others experience frequent attacks. This unpredictability is one of the most challenging aspects of living with RRMS.

Managing RRMS

While there is currently no cure for RRMS, Johns Hopkins Medicine highlights that treatment focuses on reducing the frequency and severity of relapses and slowing overall progression. Disease-modifying therapies (DMTs) are the cornerstone of RRMS management. Beyond medication, lifestyle choices such as maintaining a healthy diet, regular physical activity, getting adequate sleep, and avoiding smoking all play a role in managing symptoms and reducing relapse triggers. Physical therapy, occupational therapy, and cognitive rehabilitation further support daily functioning and independence.

Secondary-progressive MS (SPMS)

Over time, many people initially diagnosed with RRMS will notice a shift in their disease pattern. Instead of clear cycles of relapse and recovery, they begin to experience a slow, steady worsening of neurological function – even without distinct flare-ups. This transition marks the onset of Secondary-Progressive MS (SPMS).

The transition from RRMS to SPMS

Overcoming MS reports that the transition to SPMS typically occurs 10 to 20 years after an RRMS diagnosis, though timing varies considerably between individuals. Research published in PMC indicates that the transition from RRMS to SPMS is ultimately observed in about two-thirds of people with RRMS, though with modern disease-modifying therapies this proportion is declining. Notably, a large cohort study found that an estimated 10% of RRMS patients converted to SPMS at 10 years, 50% at 20 years, and 93% at 30 years – when left untreated.

One of the key challenges with SPMS is that the transition is gradual and often difficult to identify while it is happening. A review in PMC notes that SPMS is almost always diagnosed retrospectively – once a sustained pattern of progressive disability becomes clinically apparent. During the diagnostic uncertainty period, some patients may remain on RRMS therapies that are less effective for progressive disease.

What SPMS looks like clinically

In SPMS, relapses become less frequent – or may stop entirely – but neurological disability continues to increase steadily. Brigham and Women’s Hospital explains that for many people, difficulty walking is one of the first noticeable signs of this transition. As the condition advances, some individuals eventually require a cane, walker, or wheelchair. Cognitive difficulties, fatigue, spasticity, bladder and bowel issues, and pain also become more prominent and persistent.

SPMS is further classified as either active (if periodic relapses or new MRI lesions are still occurring) or non-active (if neither is present), and as either progressing or stable depending on whether disability is worsening over time. This distinction is medically important because only those with active SPMS are currently eligible for certain disease-modifying therapies.

Risk factors for earlier SPMS transition

Not everyone with RRMS transitions to SPMS at the same rate. Research identifies several factors that increase the risk of earlier conversion: older age at MS onset, higher disability levels at diagnosis, smoking, motor and cerebellar dysfunction, and the presence of spinal cord lesions. Smoking, in particular, is a modifiable risk factor – making it a meaningful target for people trying to slow their disease course.

Primary-progressive MS (PPMS)

Unlike RRMS and SPMS, Primary-Progressive MS does not begin with relapsing episodes. From the very first symptoms, the disease follows a course of continuous neurological decline – without the cycles of relapse and remission that characterise RRMS.

How PPMS differs from the start

Johns Hopkins Medicine describes PPMS as a form in which neurological function worsens steadily from the beginning, with no symptom flare-ups or remissions. While the rate of progression can vary – and there may be occasional periods of relative stability or minor temporary improvements – the overall trajectory is one of continuous decline. PPMS accounts for approximately 10% of all MS diagnoses. Crucially, unlike RRMS – which affects women far more often than men – PPMS affects men and women in roughly equal proportions.

Age at onset and typical presentation

People with PPMS tend to develop symptoms later in life than those with RRMS. On average, symptoms begin between ages 35 and 39. Roche’s clinical overview notes that a PPMS diagnosis typically occurs about 10 years later than RRMS, since doctors must observe a sustained and identifiable decline in physical abilities before confirming the diagnosis. One early and common sign is a slow but progressive decline in walking ability, as PPMS causes more damage to the spinal cord than the brain relative to RRMS.

Why PPMS is particularly challenging

PPMS involves considerably less of the acute inflammation seen in RRMS. Instead, the disease is driven more by neurodegeneration – progressive nerve cell damage that is harder to treat with conventional anti-inflammatory therapies. According to Roche, the accumulation of irreversible disability is twice as high in PPMS compared to RRMS, meaning people with PPMS rely more heavily on mobility aids or wheelchairs over time. Treatment options are more limited; only one disease-modifying therapy – ocrelizumab (Ocrevus) – has received FDA approval specifically for PPMS, whereas dozens of DMTs are available for relapsing forms of MS. Management, therefore, focuses largely on symptom relief, rehabilitation, and improving quality of life through physical and occupational therapy.

Comparing the three types: key differences at a glance

While all three forms of MS share the same underlying disease process – immune-mediated damage to myelin in the central nervous system – they differ in how that damage manifests over time. RRMS is defined by episodic flare-ups with recovery periods, affecting mostly younger women. SPMS emerges from RRMS as relapses fade and steady decline takes hold, typically after a decade or more. PPMS starts progressively from the outset, affects men and women equally, and offers fewer treatment options. Across all three types, the central challenge remains the same: managing a disease that is chronic, often unpredictable, and highly individual in its course.

For educators, caregivers, and support workers, understanding these distinctions helps in recognising where a person is in their disease journey – and what kinds of support, adaptation, and intervention are most relevant at each stage.

What do you think? How might understanding the specific stage of MS – whether RRMS, SPMS, or PPMS – change the way educators or caregivers support someone living with the condition? And given that the transition from RRMS to SPMS often goes undetected for years, what does this suggest about the importance of consistent, long-term monitoring in MS care?

References

PDF 📄

Progression of Multiple Sclerosis: Understanding RRMS, SPMS, and PPMS

Table of Contents

Why disease course classification matters 🔗

Relapsing-remitting MS (RRMS) 🔗

What happens during a relapse? 🔗

What happens during remission? 🔗

Who is diagnosed with RRMS and when? 🔗

Managing RRMS 🔗

Secondary-progressive MS (SPMS) 🔗

The transition from RRMS to SPMS 🔗

What SPMS looks like clinically 🔗

Risk factors for earlier SPMS transition 🔗

Primary-progressive MS (PPMS) 🔗

How PPMS differs from the start 🔗

Age at onset and typical presentation 🔗

Why PPMS is particularly challenging 🔗

Comparing the three types: key differences at a glance 🔗